Telemedicine and Acne inversa - TeleVersaData collection for the characterization of acne inversa patients
Recruiting
- Conditions
- L73.2Hidradenitis suppurativa
- Registration Number
- DRKS00030638
- Lead Sponsor
- ovartis Pharma GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
- Age of majority (=18 years).
- Patients with diagnosed acne inversa, suspected acne inversa or with an OnlineDoctor diagnosis.
- Patient is mentally and physically able to participate.
- Written informed consent obtained from the patient
Exclusion Criteria
Exclusion Criteria:
- Medical conditions or other limitations that, in the physician's judgment, would interfere with independent consent or completion of the questionnaires by the patient.
- Patient has already participated in the research project.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The scientific goal of the TeleVersa research project is to gain a better understanding of acne inversa patients and their individual patient journey through the healthcare system.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways in hidradenitis suppurativa are targeted by telemedicine-based patient monitoring strategies?
How does telemedicine data collection compare to standard-of-care assessments in tracking HS disease severity and flare frequency?
Which inflammatory biomarkers correlate with treatment outcomes in DRKS00030638's acne inversa patient cohort?
What adverse events are associated with telemedicine interventions in hidradenitis suppurativa management, and how are they mitigated?
How does ovartis Pharma's telemedicine approach for HS align with current biologic therapies like TNF-alpha inhibitors or IL-17 antagonists?